LPCN stock news · Lipocine Inc.
Get alerts for LPCN
Follow Lipocine Inc. (LPCN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LPCNLipocine Inc. shares news about its latest corporate presentation for investors.
NeutralLipocine filed an updated presentation for investor meetings. The notice gives no new business results or plans, so it does not change how we read the company.
Canada has approved Lipocine's TLANDO, making it easier for people to get testosterone treatment there.
Good for LPCNHealth Canada approved Lipocine's TLANDO capsules for adult men with low testosterone. This opens a path into Canada, though Verity plans to launch by the end of 2026.
12 health care companies are changing prices before the market opens on Wednesday.
NeutralLipocine's stock rose 52% to $3.20 per share. The article gives no business news to explain the move, so it does not change the company's outlook.
Lipocine Inc. has some news about TLANDO.
Good for LPCNHealth Canada approved Lipocine’s TLANDO for adult men needing testosterone replacement. This supports Lipocine’s outlook by clearing a key hurdle in Canada, though sales are not reported.
Lipocine Inc.: Other Events (LPCN)
NeutralLipocine filed a Form 8-K to announce an investor presentation at H.C. Wainwright; this routine notice does not change Lipocine's outlook.
Lipocine Inc. details leadership transitions, including the exit and election of directors, along with the appointment of new officers and their compensation arrangements (LPCN).
NeutralLipocine Inc. has filed a Form 8-K/A detailing significant changes in its leadership, including the departure and appointment of certain officers and directors. Such changes can lead to shifts in company strategy and may influence investor sentiment, making it crucial for stakeholders to monitor the situation closely.